sentence: The key dose-limiting toxicity of ATRi – CHK1i – WEE1i seen in early phase clinical trials has been dose-dependent myelosuppression ( Table 1 ) , and this has made combining these drugs with cytotoxic chemotherapies particularly challenging , sometimes compromising treatment efficacy .